Generation Bio Co. (GBIO)
After hours:
| Previous Close | 4.6700 |
| Open | 4.7400 |
| Bid | 4.2900 x 1800 |
| Ask | 4.3100 x 800 |
| Day's Range | 4.2700 - 4.8160 |
| 52 Week Range | 3.4000 - 9.5900 |
| Volume | |
| Avg. Volume | 493,029 |
| Market Cap | 286.464M |
| Beta (5Y Monthly) | 1.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.1800 |
| Earnings Date | May 03, 2023 - May 08, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.33 |
- Zacks
Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio
Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.
- Reuters
UPDATE 2-Moderna signs licensing deal with Generation Bio in push beyond COVID
Moderna Inc has entered a licensing deal with Generation Bio Co to develop treatments targeting the immune system and liver, the latest such transaction by the vaccine maker as it expands beyond its COVID shots. Generation Bio's shares rose about 13.14% to $4.40 in premarket trading on Thursday. Moderna will pay $40 million in cash upfront, and make a $36 million equity investment in Cambridge, Massachusetts-based Generation Bio.
- GlobeNewswire
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
Collaboration will extend the applications of each company’s platform through discovery and development of novel lipid nanoparticles using Generation Bio’s proprietary stealth cell-targeted lipid nanoparticle (ctLNP) delivery system Moderna has acquired an option to license Generation Bio’s ctLNP and closed-ended DNA (ceDNA) technology for two immune cell programs and two liver programs, with an additional option for a third immune cell or liver program Moderna will fund all research and develop
